349 related articles for article (PubMed ID: 19900407)
1. Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells.
Yamakawa K; Izumi Y; Takeuchi H; Yamamoto N; Kume T; Akaike A; Takahashi R; Shimohama S; Sawada H
Biochem Biophys Res Commun; 2010 Jan; 391(1):129-34. PubMed ID: 19900407
[TBL] [Abstract][Full Text] [Related]
2. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
3. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine.
Moussa CE; Wersinger C; Tomita Y; Sidhu A
Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
5. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
6. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation.
Leong SL; Pham CL; Galatis D; Fodero-Tavoletti MT; Perez K; Hill AF; Masters CL; Ali FE; Barnham KJ; Cappai R
Free Radic Biol Med; 2009 May; 46(10):1328-37. PubMed ID: 19248830
[TBL] [Abstract][Full Text] [Related]
7. Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cells.
Gómez-Santos C; Ferrer I; Santidrián AF; Barrachina M; Gil J; Ambrosio S
J Neurosci Res; 2003 Aug; 73(3):341-50. PubMed ID: 12868068
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
[TBL] [Abstract][Full Text] [Related]
9. alpha-Synuclein protects SH-SY5Y cells from dopamine toxicity.
Colapinto M; Mila S; Giraudo S; Stefanazzi P; Molteni M; Rossetti C; Bergamasco B; Lopiano L; Fasano M
Biochem Biophys Res Commun; 2006 Nov; 349(4):1294-300. PubMed ID: 16978583
[TBL] [Abstract][Full Text] [Related]
10. Alpha-synuclein overexpression reduces gap junctional intercellular communication in dopaminergic neuroblastoma cells.
Sung JY; Lee HJ; Jeong EI; Oh Y; Park J; Kang KS; Chung KC
Neurosci Lett; 2007 Apr; 416(3):289-93. PubMed ID: 17337120
[TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein knockdown attenuates MPP+ induced mitochondrial dysfunction of SH-SY5Y cells.
Wu F; Poon WS; Lu G; Wang A; Meng H; Feng L; Li Z; Liu S
Brain Res; 2009 Oct; 1292():173-9. PubMed ID: 19646423
[TBL] [Abstract][Full Text] [Related]
12. Rotenone induces apoptosis via activation of bad in human dopaminergic SH-SY5Y cells.
Watabe M; Nakaki T
J Pharmacol Exp Ther; 2004 Dec; 311(3):948-53. PubMed ID: 15280438
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis.
Alberio T; Bossi AM; Milli A; Parma E; Gariboldi MB; Tosi G; Lopiano L; Fasano M
FEBS J; 2010 Dec; 277(23):4909-19. PubMed ID: 20977677
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
Dong Z; Ferger B; Feldon J; Büeler H
J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
[TBL] [Abstract][Full Text] [Related]
15. A cell-based model of alpha-synucleinopathy for screening compounds with therapeutic potential of Parkinson's disease.
Zhao DL; Zou LB; Zhou LF; Zhu P; Zhu HB
Acta Pharmacol Sin; 2007 May; 28(5):616-26. PubMed ID: 17439717
[TBL] [Abstract][Full Text] [Related]
16. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.
Liu IH; Uversky VN; Munishkina LA; Fink AL; Halfter W; Cole GJ
Glycobiology; 2005 Dec; 15(12):1320-31. PubMed ID: 16037493
[TBL] [Abstract][Full Text] [Related]
17. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates.
Purisai MG; McCormack AL; Langston WJ; Johnston LC; Di Monte DA
Neurobiol Dis; 2005 Dec; 20(3):898-906. PubMed ID: 16006134
[TBL] [Abstract][Full Text] [Related]
18. Microarray expression analysis of human dopaminergic neuroblastoma cells after RNA interference of SNCA--a key player in the pathogenesis of Parkinson's disease.
Häbig K; Walter M; Stappert H; Riess O; Bonin M
Brain Res; 2009 Feb; 1256():19-33. PubMed ID: 19135032
[TBL] [Abstract][Full Text] [Related]
19. Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy.
Sultana Z; Paleologou KE; Al-Mansoori KM; Ardah MT; Singh N; Usmani S; Jiao H; Martin FL; Bharath MM; Vali S; El-Agnaf OM
Neuroscience; 2011 Dec; 199():303-17. PubMed ID: 22056602
[TBL] [Abstract][Full Text] [Related]
20. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.
Wakamatsu M; Ishii A; Iwata S; Sakagami J; Ukai Y; Ono M; Kanbe D; Muramatsu S; Kobayashi K; Iwatsubo T; Yoshimoto M
Neurobiol Aging; 2008 Apr; 29(4):574-85. PubMed ID: 17174013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]